Premium
The Neovessel Occlusion Efficacy of 15 1 ‐Hydroxypurpurin‐7‐Lactone Dimethyl Ester Induced with Photodynamic Therapy
Author(s) -
Lim Siang Hui,
NowakSliwinska Patrycja,
Kamarulzaman Fadzly Adzhar,
Van Den Bergh Hubert,
Wagnières Georges,
Lee Hong Boon
Publication year - 2010
Publication title -
photochemistry and photobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 131
eISSN - 1751-1097
pISSN - 0031-8655
DOI - 10.1111/j.1751-1097.2009.00684.x
Subject(s) - verteporfin , photodynamic therapy , extravasation , occlusion , chemistry , saline , nuclear medicine , medicine , surgery , macular degeneration , ophthalmology , anesthesia , pathology , choroidal neovascularization , organic chemistry
In this study, the photodynamic therapy (PDT) induced efficacy of a semi‐synthesized analogue 15 1 ‐hydroxypurpurin‐7‐lactone dimethyl ester or G2, in terms of chick chorioallantoic membrane blood vessel occlusion was evaluated in reference to verteporfin. Early formulation studies showed that G2 prepared in a system of cremophor EL 2.5% and ethanol 2.5% in saline was biocompatible up to 20 μL volume of injection. Following injection, G2 accumulation peaked within the first minute and its extravasation from intra‐ to extra‐vascular occurred somewhat slower as compared with verteporfin. In the PDT study, closure of capillaries and small neovessels was observed with 4 μg per embryo of G2 and a light dose of 20 J cm −2 at a fluence rate of 40 mW cm −2 filtered at 400–440 nm—a result that may be considered optimum for the treatment of age‐related macular degeneration (AMD). Also, partial occlusion of the large vessels was observed using the same dose of G2 and light—an effect which is desirable for cancer treatment. From this study, we conclude that G2 has the potential to be developed as a therapeutic agent for photodynamic treatment for AMD and cancer.